about
Guideline of Chronic Urticaria BeyondThe Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen ImmunotherapyGeneration and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgGSevere asthma: anti-IgE or anti-IL-5?Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations.Effects of anti-IgE in asthmatic subjects.Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.Omalizumab: the evidence for its place in the treatment of allergic asthmaTransgenic rice for allergy immunotherapyNovel targeted therapies for eosinophil-associated diseases and allergyHigh-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.Update on optimal use of omalizumab in management of asthma.Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.Optimal management of severe/refractory asthma.Structural and Physical Basis for Anti-IgE Therapy.Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.Inhibition of IgE Activity to Bind its High Affinity Receptor (FcεRIα) by Mouse Anti-IgE Cε3∼4 Monoclonal Antibody (QME5).Anti-immunoglobulin e therapyIgE-FcepsilonRI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells.IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.The binding epitopes of neurotrophin-3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin.Immunotherapy for allergies and asthma: present and futureAssessment and significance of protein-protein interactions during development of protein biopharmaceuticals.From IgE to Omalizumab.Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.Assessing analytical methods to monitor isoAsp formation in monoclonal antibodies.Structure of the omalizumab Fab.Asthma and therapeutics: recombinant therapies in asthmaCurrent and future applications of the anti-IgE antibody omalizumab.Antibody humanization by molecular dynamics simulations-in-silico guided selection of critical backmutations.Severe asthma and the omalizumab option.A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.An autonomous CDR3delta is sufficient for recognition of the nonclassical MHC class I molecules T10 and T22 by gammadelta T cells.Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody.Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction.The epidemic of asthma and allergy.Novel therapies for severe asthma in children and adults.
P2860
Q26743369-A4E761B4-7F46-4BD8-9F51-64F98F19F97BQ26771289-0B6D65A0-D742-4A55-905E-2F3F245B67E6Q27678647-E86D2EFD-6876-49FB-AEBF-C4DEE1F6B123Q28071832-C3607AF5-F37A-4822-A238-ECE0123280CDQ30333186-4E18F96B-60D1-4F35-86F9-7466B3CA18F5Q33588164-A76CC221-8055-4276-A00C-21B18B85CE99Q33774675-011CBE1C-DCB2-41F9-83F9-6BD612935F5BQ33973970-9564282F-7B3D-41E5-9A2E-4EF302CB9371Q34161259-5D5FB165-8612-464F-8D4D-30E30E890C17Q34444620-CDA09111-9910-4D9D-AC5A-8E5550F91A59Q34595292-F7786522-29B0-4EDC-8601-915043051BF3Q34623856-9E19BD24-1C78-4E07-A0E0-9352934CB07CQ34782224-5B021D78-3CE2-4C79-9037-49CDFDB11077Q35117827-0A35DB35-05CB-4BD0-8902-FEDB3A4E2C57Q35183644-0DFD7E92-4C09-4074-A7AE-3EF11F5AEE1EQ35193179-2B5C8052-7382-4C0C-B185-CB6E3619E156Q35783662-C9BC5A6B-3E96-4979-92EF-AD33D401E261Q35918874-025CD83B-540A-48FC-ABF2-EB619870F8F8Q36735617-F9F8BE76-F9E0-415B-9D3C-723996BE2311Q36834564-1CF14D44-AA14-4721-99F6-7619FEC7185BQ37468565-8FF6E197-9B3C-46B2-B277-F961B8D0F0F9Q37554168-89055E20-ABCC-45EB-9CA7-6ACB8E314677Q37639840-D5792600-42C4-4E19-A7B4-D22E3DCBACCFQ37767298-3ED50067-CD65-4D06-B898-D3213AFBE4FFQ38783040-8B25F9B4-35FB-4ADD-91D5-2BE2CFAE8A3BQ38793428-0768957D-44C0-489F-ADE8-849EA93020BAQ39012896-0BED2A7C-1C9C-4064-AF2E-3E49138B2EE6Q39252529-9E3FEA23-97F1-4F9C-A99E-FF159D0784A6Q39335284-16C6DBDB-96A7-4B48-BE80-E7A7D027A16AQ39433127-542B168E-F32E-4713-AB05-419A4E26EFBAQ40119246-375FD284-907C-4799-977D-937329DD7771Q40125548-F12EB2A1-2ECD-467E-95FF-BD719AE5A696Q40740336-7B285F56-FCA8-47C3-B9CE-154F291CBD0EQ41125439-6A518D94-0258-468C-81A5-DC0E492D1F7EQ42144048-5DE65B56-E798-4BE6-83EE-1CB9B73ED2ACQ42536548-2413DD6A-B940-449C-BF8B-D6E29395A341Q42943416-DA9AE76C-24E8-40E7-9DA8-5F1861180721Q47203998-0D9914C3-F578-4C06-AFAA-FE13252F8305Q51007928-EAF623BE-6C5C-4060-8ED1-9AA5CBB75EEBQ52668271-6262B105-1C90-416E-AB26-A7E9FF014472
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Humanization of an antibody directed against IgE
@ast
Humanization of an antibody directed against IgE
@en
Humanization of an antibody directed against IgE
@nl
type
label
Humanization of an antibody directed against IgE
@ast
Humanization of an antibody directed against IgE
@en
Humanization of an antibody directed against IgE
@nl
prefLabel
Humanization of an antibody directed against IgE
@ast
Humanization of an antibody directed against IgE
@en
Humanization of an antibody directed against IgE
@nl
P2093
P3181
P1476
Humanization of an antibody directed against IgE
@en
P2093
B M Fendly
C M Gorman
J P Porter
L G Presta
P M Jardieu
R L Shields
P304
P3181
P407
P577
1993-09-01T00:00:00Z